Aruna Bio to Participate in Upcoming Investor Conferences

2024-03-18

BOSTON and ATHENS, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced that Stephen From, Chief Executive Officer of Aruna Bio, will be presenting a corporate overview at upcoming investor conferences.

Conference and presentation details are as follows:

RESI (Redefining Early Stage Investments) South—March 25, 2024

Format: Corporate Presentation

Session Details: Therapeutics and Drug Delivery Systems, beginning at 1:00 p.m. ET

Location: The Whitley Hotel Atlanta Buckhead, Atlanta, GA

MedInvest Biotech & Pharma Investor Conference—April 3-4, 2024

Format: Corporate Presentation

Location: 55 Hudson Yards, New York, NY

If you are interested in meeting with management during the conference, please reach out to your conference representative or Aruna directly by contacting Noah Gilman, Senior Business Development Associate at ngilman@arunabio.com.

About Aruna Bio

Aruna Bio is revolutionizing CNS treatment with its proprietary neural exosome platform, targeting neurological conditions such as ALS, Alzheimer's, and stroke. Their lead product, AB126, demonstrates multiple biological activities, including crossing the blood-brain barrier, neuroprotection, and reducing neuro-inflammation, with potential for broad applicability across neurological diseases. The company's in-house cGMP facility supports their pipeline from early development to clinical trials. Aruna Bio's strategic approach includes leveraging their platform for drug delivery and exploring combination therapies, setting a foundation for addressing unmet needs in CNS treatment.

Investor Contact:

Corey Davis

LifeSci Advisors

cdavis@lifesciadvisors.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构